연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3185. Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa, Yoon-Koo Kang, Seiichi Hirota, Han-Kwang Yang & Toshirou Nishida
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2023 Sep;26(5):775-787.
Link
3184. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Sara M Tolaney, Arlene Chan, Katarina Petrakova , Suzette Delaloge , Mario Campone , Hiroji Iwata, Parvin F Peddi , Peter A Kaufman , Elisabeth De Kermadec , Qianying Liu , Patrick Cohen , Gautier Paux , Lei Wang , Nils Ternès , Eric Boitier , Seock-Ah Im
J Clin Oncol 2023 Aug 20;41(24):4014-4024
Link
3183. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz , Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios , Aditya Bardia , Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Ther Adv Med Oncol 2023 May 29;15:17588359231178125.
Link
3182. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Perna, Junji Tsurutani, Binghe Xu, Erika Hamilton, Seock-Ah Im, Zbigniew Nowecki, Joohyuk Sohn, Michelino De Laurentiis , Noelia Martínez Jañez , Barbara Adamo , Keun Seok Lee , Kyung Hae Jung , Gábor Rubovszky , Ling-Ming Tseng , Yen-Shen Lu , Yuan Yuan , Micah J Maxwell, Vincent Haddad , Sabrina S Khan , Hope S Rugo , Barbara Pistilli
Future Oncol 2023 Jun 30 [Epub ahead of print]
Link
3181. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung-Bae Kim, Toshimi Takano, Seock-Ah Im, Giuliano Borges, Joao Paulo Lima, Sercan Aksoy, Joaquin Gavila Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruiz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, Francois P Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Cai Wu, Changan Chu, Anton Egorov, Ian Krop
Lancet 2023 May 27;401(10390):1773-1785.
Link
3180. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
Xavier Pivot, Javier Cortés, Diana Lüftner, Gary H Lyman, Giuseppe Curigliano, Igor M Bondarenko, Jin-Hee Ahn, Seock-Ah Im, Maria Litwiniuk, Yaroslav V Shparyk, Gwo Fuang Ho, Nikolay V Kislov, Marek Wojtukiewicz, Tomasz Sarosiek, Yee Soo Chae, Jin Seok Ahn, Hyerin Jang, Sujung Kim, Jiwon Lee, YeChan Yoon
JAMA Netw Open
2023 Apr 3;6(4):e235822.
Link
3179. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial
Elżbieta Senkus, Suzette Delaloge, Susan M Domchek, Pierfranco Conte, Seock-Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark Robson, Nadine Tung
Int J Cancer 2023 Aug 15;153(4):803-814.
Link
3178. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Mark E Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, Allison Allen, Pierfranco Conte
Eur J Cancer 2023 Feb 14;184:39-47.
Link
3177. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment
Hyun Jung Kwon, Yujun Park, Soo Kyung Nam, Enoch Kang, Ka-Kyung Kim, Inhae Jeong, Yoonjin Kwak, Jeesun Yoon, Tae-Yong Kim, Keun-Wook Lee, Do-Youn Oh, Seock-Ah Im, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Hyung-Ho Kim, Han-Kwang Yang, Hye Seung Lee
Cancer Med 2023 May;12(9):10371-10384
Link
3176. Absence of Alpha-Synuclein Pathology in the Stomach of a Patient With Prodromal Dementia With Lewy Bodies
Shin C, Kim SI, Park SH, Shin JH, Lee CY, Kim HJ, Lee HJ, Kong SH, Suh YS, Yang HK, Jeon B.
J Mov Disord. 2023 May;16(2):213-216.
Link